中恆集團(600252.SH)擬斥1.96億元投資中恆同德醫藥健康產業基金
格隆匯11月12日丨中恆集團(600252.SH)公佈，公司擬投資由北京同德同鑫投資中心(有限合夥)(“同德同鑫”)採用有限合夥企業形式發起設立的中恆同德醫藥健康產業投資基金合夥企業(有限合夥)(暫定名，“投資基金”、“基金”)，並以同德乾元(北京)投資管理有限公司(“同德乾元”、“基金管理人”)為基金管理人。投資基金總規模擬定為人民幣2億元，公司出資人民幣1.96億元，佔基金總規模的98%；同德同鑫出資人民幣400萬元，佔基金總規模的2%。
中恆同德醫藥健康產業投資基金合夥企業(有限合夥)(暫定名，最終名稱以市場監督管理機構登記名稱為準)投資方向：符合醫藥產業未來技術發展方向的創新藥研發、整合藥物創新研發資源為主要目的，並重點對該類具有較為完善的生產、研發、銷售體系的成長期藥企進行參股型投資；同時，合夥企業亦尋找、篩選新藥研發、新藥研發服務、新一代醫療檢測與診斷等創新藥研發項目。
與醫藥健康領域的專業機構建立深度合作，利用機構項目渠道、專業投研能力，結合公司的產業背景和投資平台、團隊，尋找、篩選符合公司戰略方向的併購投資項目標的，強化資本運作力度，努力打造公司核心競爭力、不斷提升公司市值，為股東創造價值。
公司初步確立了“十三五”期間產融投相結合的發展戰略，通過設立投資基金，加速佈局醫藥健康產業鏈中具有高壁壘、高成長性的戰略環節，通過併購及參股投資改善公司產品格局和研發管線，從而為公司戰略轉型升級奠定良好基礎。
通過設立投資基金，以併購、參股等多種投融資手段，建立招商引資、招才引智的機制平台，與國內優秀的產品團隊、研發團隊、投資團隊建立資本紐帶，充分利用公司現有產業資源，為公司導入優質投資項目，打造生物醫藥產業生態鏈，能帶動和促進自治區健康產業發展。
與專業投資機構共同設立投資基金，是目前上市公司開展資本運作的重要手段之一。作為此次基金管理人的同德乾元專注於醫藥健康領域的投資，擁有豐富的資本運作經驗和廣泛的項目來源與儲備。對於該基金擬投資優質項目，同等條件下在基金退出時可優先收購，有利於增強公司獲取優質醫藥資產的能力和可持續發展的能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
